mTOR Signaling Network in Cell Biology and Human Disease

doi:10.3390/ijms232416142

Editorial

. 2022 Dec 18;23(24):16142.

doi: 10.3390/ijms232416142.

mTOR Signaling Network in Cell Biology and Human Disease

Jane J Yu¹, Elena A Goncharova²

Affiliations

¹ Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
² Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Lung Center, School of Medicine, University of California Davis, Davis, CA 95616, USA.

PMID: 36555783
PMCID: PMC9787689
DOI: 10.3390/ijms232416142

Editorial

mTOR Signaling Network in Cell Biology and Human Disease

Jane J Yu et al. Int J Mol Sci. 2022.

. 2022 Dec 18;23(24):16142.

doi: 10.3390/ijms232416142.

Authors

Jane J Yu¹, Elena A Goncharova²

Affiliations

¹ Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
² Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Lung Center, School of Medicine, University of California Davis, Davis, CA 95616, USA.

PMID: 36555783
PMCID: PMC9787689
DOI: 10.3390/ijms232416142

Abstract

The mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase that regulates multiple processes, including gene transcription, protein synthesis, ribosome biogenesis, autophagy, cell metabolism, and cell growth [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Cited by

Structural Insights into the Giardia lamblia Target of Rapamycin Homolog: A Bioinformatics Approach.
Muñoz-Muñoz PLA, Mares-Alejandre RE, Meléndez-López SG, Ramos-Ibarra MA. Muñoz-Muñoz PLA, et al. Int J Mol Sci. 2023 Jul 26;24(15):11992. doi: 10.3390/ijms241511992. Int J Mol Sci. 2023. PMID: 37569368 Free PMC article.
MSCs-derived EVs protect against chemotherapy-induced ovarian toxicity: role of PI3K/AKT/mTOR axis.
Elsherbiny NM, Abdel-Maksoud MS, Prabahar K, Mohammedsaleh ZM, Badr OAM, Dessouky AA, Salem HA, Refadah OA, Farid AS, Shamaa AA, Ebrahim N. Elsherbiny NM, et al. J Ovarian Res. 2024 Nov 11;17(1):222. doi: 10.1186/s13048-024-01545-7. J Ovarian Res. 2024. PMID: 39529187 Free PMC article.
mTOR signaling in hair follicle and hair diseases: recent progress.
Tu W, Cao YW, Sun M, Liu Q, Zhao HG. Tu W, et al. Front Med (Lausanne). 2023 Sep 4;10:1209439. doi: 10.3389/fmed.2023.1209439. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37727765 Free PMC article. Review.
Hair follicle stem cells promote epidermal regeneration under expanded condition.
Zhang Y, Cui J, Cang Z, Pei J, Zhang X, Song B, Fan X, Ma X, Li Y. Zhang Y, et al. Front Physiol. 2024 Feb 22;15:1306011. doi: 10.3389/fphys.2024.1306011. eCollection 2024. Front Physiol. 2024. PMID: 38455843 Free PMC article. Review.
mTOR Signaling: Recent Progress.
Gargalionis AN, Papavassiliou KA, Papavassiliou AG. Gargalionis AN, et al. Int J Mol Sci. 2024 Feb 23;25(5):2587. doi: 10.3390/ijms25052587. Int J Mol Sci. 2024. PMID: 38473834 Free PMC article.

See all "Cited by" articles

References

1. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004;14:1296–1302. doi: 10.1016/j.cub.2004.06.054. - DOI - PubMed
1. Popova N.V., Jucker M. The Role of mTOR Signaling as a Therapeutic Target in Cancer. Int. J. Mol. Sci. 2021;22:1743. doi: 10.3390/ijms22041743. - DOI - PMC - PubMed
1. Yin S., Liu L., Gan W. The Roles of Post-Translational Modifications on mTOR Signaling. Int. J. Mol. Sci. 2021;22:1784. doi: 10.3390/ijms22041784. - DOI - PMC - PubMed
1. Guenzle J., Akasaka H., Joechle K., Reichardt W., Venkatasamy A., Hoeppner J., Hellerbrand C., Fichtner-Feigl S., Lang S.A. Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma. Int. J. Mol. Sci. 2020;22:30. doi: 10.3390/ijms22010030. - DOI - PMC - PubMed
1. Quintero-Fabián S., Arreola R., Becerril-Villanueva E., Torres-Romero J.C., Arana-Argáez V., Lara-Riegos J., Ramírez-Camacho M.A., Alvarez-Sánchez M.E. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front. Oncol. 2019;9:1370. doi: 10.3389/fonc.2019.01370. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004;14:1296–1302. doi: 10.1016/j.cub.2004.06.054. - DOI - PubMed

[2] Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004;14:1296–1302. doi: 10.1016/j.cub.2004.06.054. - DOI - PubMed

[3] Popova N.V., Jucker M. The Role of mTOR Signaling as a Therapeutic Target in Cancer. Int. J. Mol. Sci. 2021;22:1743. doi: 10.3390/ijms22041743. - DOI - PMC - PubMed

[4] Popova N.V., Jucker M. The Role of mTOR Signaling as a Therapeutic Target in Cancer. Int. J. Mol. Sci. 2021;22:1743. doi: 10.3390/ijms22041743. - DOI - PMC - PubMed

[5] Yin S., Liu L., Gan W. The Roles of Post-Translational Modifications on mTOR Signaling. Int. J. Mol. Sci. 2021;22:1784. doi: 10.3390/ijms22041784. - DOI - PMC - PubMed

[6] Yin S., Liu L., Gan W. The Roles of Post-Translational Modifications on mTOR Signaling. Int. J. Mol. Sci. 2021;22:1784. doi: 10.3390/ijms22041784. - DOI - PMC - PubMed

[7] Guenzle J., Akasaka H., Joechle K., Reichardt W., Venkatasamy A., Hoeppner J., Hellerbrand C., Fichtner-Feigl S., Lang S.A. Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma. Int. J. Mol. Sci. 2020;22:30. doi: 10.3390/ijms22010030. - DOI - PMC - PubMed

[8] Guenzle J., Akasaka H., Joechle K., Reichardt W., Venkatasamy A., Hoeppner J., Hellerbrand C., Fichtner-Feigl S., Lang S.A. Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma. Int. J. Mol. Sci. 2020;22:30. doi: 10.3390/ijms22010030. - DOI - PMC - PubMed

[9] Quintero-Fabián S., Arreola R., Becerril-Villanueva E., Torres-Romero J.C., Arana-Argáez V., Lara-Riegos J., Ramírez-Camacho M.A., Alvarez-Sánchez M.E. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front. Oncol. 2019;9:1370. doi: 10.3389/fonc.2019.01370. - DOI - PMC - PubMed

[10] Quintero-Fabián S., Arreola R., Becerril-Villanueva E., Torres-Romero J.C., Arana-Argáez V., Lara-Riegos J., Ramírez-Camacho M.A., Alvarez-Sánchez M.E. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front. Oncol. 2019;9:1370. doi: 10.3389/fonc.2019.01370. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

mTOR Signaling Network in Cell Biology and Human Disease

Affiliations

mTOR Signaling Network in Cell Biology and Human Disease

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous